Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update [Yahoo! Finance]
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update
Favourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired Stock [Yahoo! Finance]
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 [Yahoo! Finance]